Beam Net Income Applicable To Common Shares from 2010 to 2026
| BEAM Stock | USD 27.89 0.03 0.11% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -234.2 M | Current Value -245.9 M | Quarterly Volatility 81.4 M |
Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.5 M, Interest Expense of 59.3 M or Selling General Administrative of 134.7 M, as well as many indicators such as Price To Sales Ratio of 35.11, Dividend Yield of 0.0 or PTB Ratio of 2.63. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
Beam | Net Income Applicable To Common Shares | Build AI portfolio with Beam Stock |
Evaluating Beam Therapeutics's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Beam Therapeutics's fundamental strength.
Latest Beam Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Beam Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Beam Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Beam Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Beam Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (174,943,201) | |
| Coefficient Of Variation | (46.52) | |
| Mean Deviation | 70,878,471 | |
| Median | (117,325,000) | |
| Standard Deviation | 81,388,239 | |
| Sample Variance | 6624T | |
| Range | 279.6M | |
| R-Value | (0.74) | |
| Mean Square Error | 3174.8T | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | (11,960,120) | |
| Total Sum of Squares | 105984.7T |
Beam Net Income Applicable To Common Shares History
About Beam Therapeutics Financial Statements
Beam Therapeutics investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -234.2 M | -245.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Beam Therapeutics Correlation against competitors. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.